Carcinomas News and Research RSS Feed - Carcinomas News and Research

Abbvie announces multiple study results of veliparib investigational compound in NSCLC patients

Abbvie announces multiple study results of veliparib investigational compound in NSCLC patients

AbbVie released interim results from an ongoing Phase 2 study of its investigational compound veliparib in combination with chemotherapy, which showed a 35 percent improvement (P-value=0.14) in progression-free survival (PFS) and a 30 percent improvement (P-value=0.21) in overall survival (OS) in patients with previously untreated metastatic or advanced non-small cell lung cancer (NSCLC). [More]
Dabrafenib shows significant anti-tumour activity in BRAF V600E mutant non-small cell lung cancer

Dabrafenib shows significant anti-tumour activity in BRAF V600E mutant non-small cell lung cancer

The BRAF inhibitor dabrafenib has significant anti-tumour activity in patients with advanced BRAF V600E mutant non-small cell lung cancer whose disease has progressed after chemotherapy, according to phase II data presented at the ESMO 2014 Congress in Madrid, Spain. [More]
Oral afatinib significantly improves progression-free survival in patients with head and neck cancer

Oral afatinib significantly improves progression-free survival in patients with head and neck cancer

The tyrosine kinase inhibitor afatinib significantly improved progression-free survival compared to methotrexate in patients with recurrent or metastatic squamous cell carcinoma of the head and neck after failure of platinum-based chemotherapy, the results of a phase III trial show. [More]
Genetic mutation caused by ultraviolet light is likely driving force behind human skin cancers

Genetic mutation caused by ultraviolet light is likely driving force behind human skin cancers

A genetic mutation caused by ultraviolet light is likely the driving force behind millions of human skin cancers, according to researchers at the Stanford University School of Medicine. [More]
KIT spinoff amcure develops tumor therapeutic agents to reduce mortality rate

KIT spinoff amcure develops tumor therapeutic agents to reduce mortality rate

There is an urgent need for medical agents to treat metastatic tumors. In case of pancreatic cancer, one of the most aggressive types of cancer that is often detected late, 95% of the patients die within five years after the diagnosis. [More]
US lung cancer rates uncover trends related to cancer subtype, sex, race/ethnicity and age

US lung cancer rates uncover trends related to cancer subtype, sex, race/ethnicity and age

A new analysis confirms that US lung cancer rates are declining overall, but it also uncovers previously unrecognized trends related to cancer subtype, sex, race/ethnicity, and age. [More]
Research points to new direction for potential therapies to treat mucoepidermoid carcinoma

Research points to new direction for potential therapies to treat mucoepidermoid carcinoma

Research conducted at the Florida campus of The Scripps Research Institute has discovered links between a set of genes known to promote tumor growth and mucoepidermoid carcinoma, an oral cancer that affects the salivary glands. The discovery could help physicians develop new treatments that target the cancer's underlying genetic causes. [More]
Montefiore-Einstein investigators to present new findings from eight abstracts at IFHNOS 2014

Montefiore-Einstein investigators to present new findings from eight abstracts at IFHNOS 2014

Clinicians and researchers from Montefiore Medical Center and the Albert Einstein College of Medicine of Yeshiva University will present new findings from eight abstracts at the International Federation of Head and Neck Oncologic Societies World Congress being held July 26 - July 30 in New York. [More]
CFDA approves CASI's ENMD-2076 Phase II trial in triple-negative breast cancer patients

CFDA approves CASI's ENMD-2076 Phase II trial in triple-negative breast cancer patients

CASI Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, announced today that China's Food and Drug Administration has approved the Company's application to conduct a Phase II clinical trial in triple-negative breast cancer (TNBC) patients in China for its proprietary drug candidate, ENMD-2076. [More]
Metvix PDT now available at Odette Cancer Centre as additional treatment option for NMSC patients

Metvix PDT now available at Odette Cancer Centre as additional treatment option for NMSC patients

The Odette Cancer Centre at Sunnybrook Health Sciences Centre in conjunction with Galderma Canada are pleased to announce that Metvix PDT (Photodynamic Therapy), is now available at the Odette Cancer Centre in Toronto as an additional treatment option for patients with NMSC (non-melanoma skin cancer). [More]
Research demonstrates new computer software to help diagnose cancer cells

Research demonstrates new computer software to help diagnose cancer cells

In pathology, cells and cell nuclei are usually examined using a microscope for bio-marker expressions in tumours. This analysis is used to weigh up the treatment options for patients who have cancer, for example. [More]
Researchers develop new software to identify severity of cancer

Researchers develop new software to identify severity of cancer

Together with the company Tissuegnostics, the pathologist Lukas Kenner and his colleagues have developed a software that is able to identify cancer cells in tissue sections and demonstrate the presence of specific biomarkers on cells. The overall information provides a precise picture of the disease and leads to the most suitable treatment. [More]
CASI's ENMD-2076 gets FDA Orphan Drug designation for HCC treatment

CASI's ENMD-2076 gets FDA Orphan Drug designation for HCC treatment

CASI Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, announced today that its orally-active, Aurora A/angiogenic kinase inhibitor, ENMD-2076, has received Orphan Drug designation from the U.S. Food and Drug Administration for the treatment of hepatocellular carcinoma (HCC). [More]
Loss of p62 protein in cells and tissue surrounding a tumor can influence tumor growth

Loss of p62 protein in cells and tissue surrounding a tumor can influence tumor growth

A team of scientists from Sanford Burnham Medical Research Institute has found that the loss of a protein called p62 in the cells and tissue surrounding a tumor can enhance the growth and progression of tumors. [More]
Exposure to ultraviolet radiation lamps used for indoor tanning increases risk of developing BCC

Exposure to ultraviolet radiation lamps used for indoor tanning increases risk of developing BCC

Dartmouth researchers have found that early exposure to the ultraviolet radiation lamps used for indoor tanning is related to an increased risk of developing basal cell carcinomas (BCC) at a young age. [More]
FDA accepts Pharmacyclics' IMBRUVICA sNDA for review

FDA accepts Pharmacyclics' IMBRUVICA sNDA for review

Pharmacyclics, Inc. today announced that the U.S. Food and Drug Administration has accepted for filing its supplemental New Drug Application (sNDA) to support the review of IMBRUVICA (ibrutinib) in the treatment of patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who have received at least one prior therapy for a full approval. [More]
Data from Caris Registry clinical outcomes presented at ASCO annual meeting

Data from Caris Registry clinical outcomes presented at ASCO annual meeting

Caris Life Sciences and investigators from Inova Fairfax Hospital presented the first clinical outcomes data presentation from the Caris Registry™ at the 50th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill., this weekend. [More]
Study suggests new targets for treating rare genetic disorder and cancer

Study suggests new targets for treating rare genetic disorder and cancer

The combined action of two enzymes, Srs2 and Exo1, prevents and repairs common genetic mutations in growing yeast cells, according to a new study led by scientists at NYU Langone Medical Center. [More]
International study provides hope to patients with advanced prostate cancer

International study provides hope to patients with advanced prostate cancer

An international study carried out with involvement of the MedUni Vienna is giving hope to patients with advanced prostate cancer. In just a few years' time, Ipilumumab could be approved as a treatment for the world's third-most common type of cancer. [More]
EntreMed reports net loss of $1.5M in first quarter 2014

EntreMed reports net loss of $1.5M in first quarter 2014

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, today reported financial results for the three months ended March 31, 2014. [More]